Insulin degludec: Overview of a novel ultra long-acting basal insulin
All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing. Insulin degludec is a novel acylated basal insulin with a unique mec...
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Julkaistu: |
2013
|